We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
28 hedge funds and large institutions have $100M invested in Crescent Biopharma in 2014 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
8% more capital invested
Capital invested by funds: $93M → $100M (+$7.08M)
4% more funds holding
Funds holding: 27 → 28 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Holders
28
Holders Change
+1
Holders Change %
+3.7%
% of All Funds
0.75%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
5
Increased
8
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
JP Morgan Chase
New York
|
+$787K |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$715K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$353K |
| 4 |
SIM
Spark Investment Management
New York
|
+$339K |
| 5 |
Blackstone Inc
New York
|
+$130K |
Top Sellers
| 1 |
Franklin Resources
San Mateo,
California
|
-$204K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$97K |
| 3 |
BPC
Banque Pictet & Cie
Geneva 73,
Switzerland
|
-$88K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$50.1K |
| 5 |
Goldman Sachs
New York
|
-$43K |
